The US Food and Drug Administration (US FDA) has given an all clear to Shilpa Medicare‘s formulation manufacturing facility at Jadcherla in Telangana. In an interview to CNBC-TV18, Vishnukant Bhutada, MD of the company spoke about the same.
Vishnukant Bhutada, MD, Shilpa Medicare said sales was low due to expansion and R&D work. He added that the past expansions will start reaping benefits from this year onwards.